Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2018065938) SCHÉMA POSOLOGIQUE D'AVÉLUMAB POUR LE TRAITEMENT DU CANCER
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

Claims

1. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 5-10 mg/kg Q1 W.

2. The method of claim 1 , wherein the dosing regimen is 5 mg/kg Q1 W.

3. The method of claim 1 , wherein the dosing regimen is 10 mg/kg Q1W.

4. The method of claim 1 , wherein the dosing regimen is 8 mg/kg Q1W.

5. The method of any of claims 1 -4, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

6. The method of claim 5, wherein the cancer is NSCLC.

7. The method of claim 5, wherein the cancer is MCC.

8. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 1 1 -20 mg/kg Q2W.

9. The method of claim 8 wherein the dosing regimen is 15 mg/kg Q2W.

10. The method of claim 8, wherein the dosing regimen is 20 mg/kg Q2W.

1 1. The method of claim 8, wherein the dosing regimen is 17 mg/kg Q2W.

12. The method of any of claims 8-1 1 , wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

13. The method of claim 12, wherein the cancer is NSCLC.

14. The method of claim 12, wherein the cancer is MCC.

15. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 15-30 mg/kg Q3W.

16. The method of claim 15 wherein the dosing regimen is 15 mg/kg Q3W.

17. The method of claim 15, wherein the dosing regimen is 20 mg/kg Q3W.

18. The method of claim 15, wherein the dosing regimen is 25 mg/kg Q3W.

19. The method of claim 15, wherein the dosing regimen is 30 mg/kg Q3W.

20. The method of any of claims 15-19, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

21. The method of claim 20, wherein the cancer is NSCLC.

22. The method of claim 20, wherein the cancer is MCC.

23. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of X mg/kg Q1 W for n weeks followed by Y mg/kg Q2W, wherein X is 5-20, Y is 10-20, n is 6, 12 or 18.

24. The method of claim 23, wherein X is 5-20, Y is 10, n is 6 or 12.

25. The method of claim 24, wherein X is 10, Y is 10, n is 12.

26. The method of claim 24, wherein X is 10, Y is 10, n is 6.

27. The method of claim 24, wherein X is 15, Y is 10, n is 12.

28. The method of claim 24, wherein X is 5, Y is 10, n is 12.

29. The method of claim 24, wherein X is 8, Y is 10 and n is 12.

30. The method of any of claims 23-29, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

31. The method of claim 30, wherein the cancer is NSCLC.

32. The method of claim 30, wherein the cancer is MCC.

33. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 400-800 mg flat dose Q1W.

34. The method of claim 33, wherein the dosing regimen is 400 mg flat dose Q1W.

35. The method of claim 33, wherein the dosing regimen is 800 mg flat dose Q1W.

36. The method of claim 33, wherein the dosing regimen is 600 mg flat dose Q1W.

37. The method of any of claims 33 to 37, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

38. The method of claim 37, wherein the cancer is NSCLC.

39. The method of claim 37, wherein the cancer is MCC.

40. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 880 - 1600 mg flat dose Q2W.

41. The method of claim 40, wherein the dosing regimen is 1200 mg flat dose Q2W.

42. The method of claim 40, wherein the dosing regimen is 1600 mg flat dose Q2W.

43. The method of any of claims 40-42, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

44. The method of claim 43, wherein the cancer is NSCLC.

45. The method of claim 43, wherein the cancer is MCC.

46. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 1200 - 2400 mg flat dose Q3W.

47. The method of claim 46, wherein the dosing regimen is 1200 mg flat dose Q3W.

48. The method of any of claims 46 to 47, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

49. The method of claim 48, wherein the cancer is NSCLC.

50. The method of claim 49, wherein the cancer is MCC.

51. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 400-1600mg Q1W for n weeks followed by 800-1600mg Q2W, wherein n is 6, 12 or 18.

52. The method of claim 51 , wherein the dosing regimen is 800 mg Q1 W for n weeks, followed by 800 mg Q2W, n is 6 or 12.

53. The method of claim 52, wherein n is 12.

54. The method of claim 52, n is 6.

55. The method of claim 51 , wherein the dosing regimen is 1200 mg Q1W for n weeks followed by 800 mg Q2W, wherein n is 12.

56. The method of claim 51 , wherein the dosing regimen is 400mg QlW for n weeks followed by 800 mg Q2W, wherein n is 12.

57. The method of claim 51 , wherein the dosing regimen is 640mg Q1 W for n weeks followed by 800 mg Q2W, wherein n is 12.

58. The method of any of claims 51 -57, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

59. The method of claim 58, wherein the cancer is NSCLC.

60. The method of claim 59, wherein the cancer is MCC.

61. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen of 400-800 mg flat dose Q2W.

62. The method of claim 61 , wherein the dosing regimen is 800 mg flat dose Q2W.

63. The method of any of claims 61 -62, wherein the cancer is selected from the group consisting of MCC, NSCLC, RCC, bladder cancer, ovarian cancer, head and neck cancer and gastric cancer.

64. The method of claim 63, wherein the cancer is NSCLC.

65. The method of claim 64, wherein the cancer is MCC.

66. The method of any of the proceeding claims, wherein the tumor proportion score of PD-L1 expression is 1 % and above, 5% and above, 10% and above, 20% and above, 30% and above, 40% and above, 50% and above, 60% and above, 70% and above, 80% and above 95% and above, or 95% and above.

67. The method of claim 66, wherein the tumor proportion score (TPS) of PD-L1 expression is 50% and above.

68. A method of treating a cancer in a patient, comprising administering avelumab to the patient according to a dosing regimen selected from the group consisting of 800 mg Q1W for 12 weeks followed by 800 mg Q2W, 10 mg/kg Q1W for 12 weeks followed by 10 mg/kg Q2W and 1200 mg Q3W, and wherein the tumor proportion score of PD-L1 expression is 5% and above, 20% and above, 50% and above or 80% and above.

69. The method of claim 68, wherein the tumor proportion score of PD-L1 expression is 50% and above and cancer is non-small cell lung cancer.